TR200103361T2 - 1-[4-(5-Siyanoindol-3-il)butil]-4- (2-karbamoilbenzofuran-5-il) piperazin'in ve fizyolojik olarak kabul edilebilir tuzlarının yeni kullanımı. - Google Patents
1-[4-(5-Siyanoindol-3-il)butil]-4- (2-karbamoilbenzofuran-5-il) piperazin'in ve fizyolojik olarak kabul edilebilir tuzlarının yeni kullanımı.Info
- Publication number
- TR200103361T2 TR200103361T2 TR2001/03361T TR200103361T TR200103361T2 TR 200103361 T2 TR200103361 T2 TR 200103361T2 TR 2001/03361 T TR2001/03361 T TR 2001/03361T TR 200103361 T TR200103361 T TR 200103361T TR 200103361 T2 TR200103361 T2 TR 200103361T2
- Authority
- TR
- Turkey
- Prior art keywords
- discomfort
- cyanoindol
- butyl
- piperazine
- physiologically acceptable
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 title abstract 2
- 230000001568 sexual effect Effects 0.000 abstract 3
- 208000008811 Agoraphobia Diseases 0.000 abstract 2
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 230000037328 acute stress Effects 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000009429 distress Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 208000013465 muscle pain Diseases 0.000 abstract 1
- 230000035882 stress Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- RPZBRGFNBNQSOP-UHFFFAOYSA-N vilazodone hydrochloride Chemical compound Cl.C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 RPZBRGFNBNQSOP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Addiction (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99109295 | 1999-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR200103361T2 true TR200103361T2 (tr) | 2002-05-21 |
Family
ID=8238153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2001/03361T TR200103361T2 (tr) | 1999-05-27 | 2000-05-16 | 1-[4-(5-Siyanoindol-3-il)butil]-4- (2-karbamoilbenzofuran-5-il) piperazin'in ve fizyolojik olarak kabul edilebilir tuzlarının yeni kullanımı. |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US6900212B1 (enExample) |
| EP (3) | EP1736158B1 (enExample) |
| JP (2) | JP4884588B2 (enExample) |
| KR (1) | KR100683367B1 (enExample) |
| CN (3) | CN1679577A (enExample) |
| AR (1) | AR024112A1 (enExample) |
| AT (3) | ATE263564T1 (enExample) |
| AU (1) | AU771778B2 (enExample) |
| BR (1) | BR0010948A (enExample) |
| CA (3) | CA2694866A1 (enExample) |
| CY (2) | CY1105750T1 (enExample) |
| CZ (1) | CZ295623B6 (enExample) |
| DE (3) | DE60042710D1 (enExample) |
| DK (3) | DK1410800T3 (enExample) |
| ES (3) | ES2219342T3 (enExample) |
| HK (1) | HK1048444B (enExample) |
| HU (1) | HU229059B1 (enExample) |
| IL (2) | IL146707A0 (enExample) |
| MX (1) | MXPA01012172A (enExample) |
| MY (1) | MY135627A (enExample) |
| NO (2) | NO322120B1 (enExample) |
| PL (3) | PL199650B1 (enExample) |
| PT (3) | PT1185272E (enExample) |
| RU (1) | RU2237477C2 (enExample) |
| SI (2) | SI1185272T1 (enExample) |
| SK (1) | SK287851B6 (enExample) |
| TR (1) | TR200103361T2 (enExample) |
| TW (1) | TW518218B (enExample) |
| UA (1) | UA74337C2 (enExample) |
| WO (1) | WO2000072832A2 (enExample) |
| ZA (1) | ZA200110485B (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| UA76130C2 (en) | 2000-11-20 | 2006-07-17 | Merck Patent Gmbh | Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome |
| DE10112151A1 (de) * | 2001-03-14 | 2002-09-19 | Merck Patent Gmbh | Substituierte Benzofuran-2-carbonsäureamide |
| UA76758C2 (uk) * | 2001-06-19 | 2006-09-15 | Мерк Патент Гмбх | Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину |
| DE10217006A1 (de) * | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
| DE10305739A1 (de) * | 2003-02-11 | 2004-08-19 | Merck Patent Gmbh | Benzofuranderivate |
| US20040192730A1 (en) * | 2003-03-13 | 2004-09-30 | Dynogen Pharmaceuticals, Inc. | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction |
| US7893261B2 (en) | 2004-03-26 | 2011-02-22 | Baylor University | Serotonin reuptake inhibitors |
| MX2008015226A (es) | 2006-05-30 | 2008-12-12 | Astrazeneca Ab | Derivados de 1,3,4-oxadiazol como inhibidores de dgat1. |
| AR069802A1 (es) | 2007-12-20 | 2010-02-17 | Astrazeneca Ab | Compuestos de carbamoilo como inhibidores de dgat1 190 |
| MX2011014018A (es) | 2009-06-19 | 2012-02-22 | Astrazeneca Ab | Pirazincarboxamidas como inhibidores de dgati. |
| ES2447295T3 (es) | 2009-11-06 | 2014-03-11 | Sk Biopharmaceuticals Co., Ltd. | Métodos para el tratamiento del trastorno de déficit de atención/hiperactividad |
| EP2496227B1 (en) | 2009-11-06 | 2019-05-22 | SK Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| US9708300B2 (en) | 2011-03-20 | 2017-07-18 | Cadila Healthcare Limited | Amorphous form of vilazodone hydrochloride and process for its preparation |
| CN102949364A (zh) * | 2011-08-30 | 2013-03-06 | 天津药物研究院 | 一种含有效成分盐酸维拉佐酮的缓释片 |
| AU2013273868A1 (en) | 2012-06-13 | 2015-02-05 | Apotex Inc. | Forms of Vilazodone and processes for the preparation thereof |
| CN102860993A (zh) * | 2012-10-16 | 2013-01-09 | 北京诚创思达医药科技有限公司 | 一种盐酸维拉唑酮快速释放片剂及其制备方法 |
| WO2014064715A2 (en) | 2012-10-22 | 2014-05-01 | Cadila Healthcare Limited | Amorphous form of vilazodone hydrochloride and process for preparing thereof |
| CN102977083A (zh) * | 2012-12-17 | 2013-03-20 | 南京海纳医药科技有限公司 | 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法 |
| CA3216579A1 (en) | 2013-01-22 | 2014-07-31 | Vistagen Therapeutics, Inc. | Dosage forms and therapeutic uses of l-4-chlorokynurenine |
| EP2824104A1 (en) | 2013-07-12 | 2015-01-14 | Sandoz AG | Process for the preparation of form III of Vilazodone hydrochloride |
| DK3297619T3 (da) * | 2015-05-22 | 2022-08-15 | Vistagen Therapeutics Inc | Terapeutiske anvendelser af L-4-chlorkynurenin |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2672052B1 (fr) * | 1991-01-28 | 1995-05-24 | Esteve Labor Dr | Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments. |
| SE9201239D0 (sv) * | 1992-04-21 | 1992-04-21 | Kabi Pharmacia Ab | Agents for treating substance abuse disorders |
| DE4333254A1 (de) * | 1993-09-30 | 1995-04-06 | Merck Patent Gmbh | Piperidine und Piperazine |
| GB9406857D0 (en) * | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| DE19514567A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Benzofurane |
| US5763457A (en) * | 1995-11-13 | 1998-06-09 | Eli Lilly And Company | Method for treating anxiety |
| US5914394A (en) * | 1997-03-27 | 1999-06-22 | Millenium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| US5900420A (en) * | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
| US6470933B1 (en) * | 1998-03-09 | 2002-10-29 | Pirelli Pneumatici S.P.A. | Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire |
| FR2781671A1 (fr) * | 1998-07-28 | 2000-02-04 | Synthelabo | Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique |
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| EP1612563A3 (en) * | 2001-09-11 | 2009-12-09 | JTEKT Corporation | Magnetic pulser ring |
| FR2844591B1 (fr) * | 2002-09-13 | 2005-04-15 | Arvinmeritor Light Vehicle Sys | Dispositif de determination du deplacement d'un arbre |
-
1999
- 1999-11-15 TW TW088119882A patent/TW518218B/zh not_active IP Right Cessation
-
2000
- 2000-05-16 EP EP06017231A patent/EP1736158B1/en not_active Expired - Lifetime
- 2000-05-16 SI SI200030423T patent/SI1185272T1/xx unknown
- 2000-05-16 HK HK03100617.0A patent/HK1048444B/zh not_active IP Right Cessation
- 2000-05-16 PL PL383406A patent/PL199650B1/pl unknown
- 2000-05-16 CA CA2694866A patent/CA2694866A1/en not_active Abandoned
- 2000-05-16 DE DE60042710T patent/DE60042710D1/de not_active Expired - Lifetime
- 2000-05-16 CN CNA2005100544177A patent/CN1679577A/zh active Pending
- 2000-05-16 ES ES00935031T patent/ES2219342T3/es not_active Expired - Lifetime
- 2000-05-16 KR KR1020017015141A patent/KR100683367B1/ko not_active Expired - Fee Related
- 2000-05-16 AT AT00935031T patent/ATE263564T1/de active
- 2000-05-16 CN CNB008081352A patent/CN1198618C/zh not_active Expired - Fee Related
- 2000-05-16 IL IL14670700A patent/IL146707A0/xx active IP Right Grant
- 2000-05-16 SI SI200030902T patent/SI1410800T1/sl unknown
- 2000-05-16 DE DE60009697T patent/DE60009697T2/de not_active Expired - Lifetime
- 2000-05-16 CA CA2615271A patent/CA2615271C/en not_active Expired - Fee Related
- 2000-05-16 DK DK04001441T patent/DK1410800T3/da active
- 2000-05-16 BR BR0010948-7A patent/BR0010948A/pt not_active Application Discontinuation
- 2000-05-16 PL PL383006A patent/PL200490B1/pl unknown
- 2000-05-16 SK SK1646-2001A patent/SK287851B6/sk not_active IP Right Cessation
- 2000-05-16 TR TR2001/03361T patent/TR200103361T2/xx unknown
- 2000-05-16 MX MXPA01012172A patent/MXPA01012172A/es active IP Right Grant
- 2000-05-16 DK DK06017231T patent/DK1736158T3/da active
- 2000-05-16 JP JP2000620944A patent/JP4884588B2/ja not_active Expired - Fee Related
- 2000-05-16 PT PT00935031T patent/PT1185272E/pt unknown
- 2000-05-16 EP EP04001441A patent/EP1410800B1/en not_active Expired - Lifetime
- 2000-05-16 CN CN200910113677A patent/CN101869565A/zh active Pending
- 2000-05-16 PT PT04001441T patent/PT1410800E/pt unknown
- 2000-05-16 PL PL352373A patent/PL199516B1/pl unknown
- 2000-05-16 US US09/979,922 patent/US6900212B1/en not_active Expired - Lifetime
- 2000-05-16 AU AU50663/00A patent/AU771778B2/en not_active Ceased
- 2000-05-16 AT AT04001441T patent/ATE337008T1/de active
- 2000-05-16 CZ CZ20014226A patent/CZ295623B6/cs not_active IP Right Cessation
- 2000-05-16 ES ES06017231T patent/ES2330774T3/es not_active Expired - Lifetime
- 2000-05-16 PT PT06017231T patent/PT1736158E/pt unknown
- 2000-05-16 AT AT06017231T patent/ATE438399T1/de active
- 2000-05-16 HU HU0201275A patent/HU229059B1/hu not_active IP Right Cessation
- 2000-05-16 DE DE60030338T patent/DE60030338T2/de not_active Expired - Lifetime
- 2000-05-16 DK DK00935031T patent/DK1185272T3/da active
- 2000-05-16 ES ES04001441T patent/ES2271707T3/es not_active Expired - Lifetime
- 2000-05-16 RU RU2001133342A patent/RU2237477C2/ru not_active IP Right Cessation
- 2000-05-16 WO PCT/EP2000/004376 patent/WO2000072832A2/en not_active Ceased
- 2000-05-16 CA CA002372668A patent/CA2372668C/en not_active Expired - Fee Related
- 2000-05-16 EP EP00935031A patent/EP1185272B1/en not_active Expired - Lifetime
- 2000-05-16 UA UA2001128861A patent/UA74337C2/uk unknown
- 2000-05-25 MY MYPI20002314A patent/MY135627A/en unknown
- 2000-05-26 AR ARP000102575A patent/AR024112A1/es unknown
-
2001
- 2001-11-22 IL IL146707A patent/IL146707A/en not_active IP Right Cessation
- 2001-11-26 NO NO20015746A patent/NO322120B1/no not_active IP Right Cessation
- 2001-12-20 ZA ZA200110485A patent/ZA200110485B/en unknown
-
2004
- 2004-11-23 US US10/994,226 patent/US7371756B2/en not_active Expired - Lifetime
-
2006
- 2006-04-06 NO NO20061562A patent/NO324230B1/no not_active IP Right Cessation
- 2006-11-02 CY CY20061101575T patent/CY1105750T1/el unknown
-
2007
- 2007-11-28 US US11/946,149 patent/US7642261B2/en not_active Expired - Fee Related
-
2009
- 2009-10-14 CY CY20091101063T patent/CY1109472T1/el unknown
- 2009-11-17 US US12/620,049 patent/US20100063062A1/en not_active Abandoned
-
2011
- 2011-02-10 JP JP2011027903A patent/JP2011148799A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105750T1 (el) | Χρηση της 1-4-(5-κυανοινδολ-3-υλο)βουτυλο-4(2-καρβαμουλοβενζοφουραν-5-υλο)πιπepαζινης και των φυσιολογικα αποδεκτων αλατων αυτης | |
| RU2489148C2 (ru) | Ингибитор активации stat3/5 | |
| BR9610385A (pt) | Novas 4-(oxalcoxifenil)-3-óxi-piperidinas para tratamento de insuficiência cardiáca e renal | |
| DE69424893D1 (de) | Enantiomere von 1-[(4-Chlorophenyl)phenylmethyl]-4-[(4-Methylphenyl)sulfonyl]piperazin | |
| TR200101020T2 (tr) | Aminobütirik asit türevleri | |
| DE60230869D1 (de) | 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| ATE240730T1 (de) | Verwendung von levobupivacaine in gesichtschirugie | |
| DE60103927D1 (de) | Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems | |
| ATE303379T1 (de) | 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| DE69811248D1 (de) | Verwendung eines 5ht2 rezeptor-antagonisten zur behandlung von schlafapnoe | |
| RU2003117446A (ru) | Косметический способ лечения кожи | |
| ATE360002T1 (de) | Verfahren zur herstellung von n1-(2'-pyridyl)-1,2-propandiaminsulfamidsäure und ihre verwendung zur herstellung von biologisch aktiven piperazinen | |
| Bardach et al. | Relationship between the sequence of lip and palate repair and maxillary growth: an experimental study in beagles | |
| ATE510543T1 (de) | Verwendung cilobradines oder seiner pharmazeutisch annehmbaren salze für die behandlung oder prävention von herzinsuffizienz | |
| DE60202679D1 (de) | 4-(phenylpiperidin-4-ylidenmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| ATE313528T1 (de) | 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen,angst oder gastrointestinalen störungen | |
| ATE313529T1 (de) | 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen,angst oder gastrointestinalen störungen | |
| ATE302006T1 (de) | Therapeutische verwendung von d-threo- methylphenidate zur behandlung von aufmerksamkeitsmangel-hyperaktivitätsstörungen | |
| KR880006207A (ko) | 알레르기 치료제로서 유용한 1-아릴옥시-4-[(4-아릴)-1- 피페라지닐]-2- 부탄올 | |
| ATE359772T1 (de) | Endothelin-niveau senkende mittel | |
| DE60128130D1 (de) | Verwendung des blutgerinnungsfaktors xiii für die behandlung der hämophilie a | |
| DE602004022540D1 (de) | Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes | |
| Bhatia et al. | Nasal deformity: a profile | |
| Doǧru et al. | Nasal septal clip (Çiǧdem clip) | |
| Kohn | Discussion: Fibrous Union of the Mandible: A Review of 27 Patients |